An interventional study of Vagal Nerve Stimulation and Sham stimulation in Irritable Bowel Syndrome, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-02.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center — 1 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · Maastricht University Medical Center.
Among the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 14th registered.
1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.
Browse Irritable Bowel Syndrome studies →1 of the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center is open now, in 1 country.
By country, each count listing its studies:
Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 166 is above the median of 70 across 900 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 50 across the 12 interventional studies, 392 across the 2 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are:
In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode.
Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
transcutaneous auricular vagal nerve stimulation, for 8 weeks at least one hour a day
Device: Vagal Nerve Stimulation
sham stimulation with a non-conducting electrode, for 8 weeks at least one hour a day
Device: Sham stimulation
Transcutaneous Auricular Vagal Nerve Stimulation
Sham stimulation with a non-conduction electrode
Clinical meaningful decrease in severity of GI-symptoms
Measuring IBS-SSS, defined as a decrease of at least 50 points
Time frame: at the end of the 8 week treatment period
Predictive value of neuro-signature
The value of the multimodal neuro-signature in the prediction of clinical response to tVNS in IBS-patients.
Time frame: at the end of the 8 week treatment period
adverse events
Number and severity of adverse events
Time frame: at the end of the 8 week treatment period
Anxiety/depression
Symptoms of anxiety and depression measured using PHQ-9 and GAD-7
Time frame: at the end of the 8 week treatment period
Cost-effectiveness
Direct and indirect costs made during the treatment period
Time frame: at follow up moment 2 (6 months after 8 week treatment period)
Time the device was used
The amount of time patients used the tVNS device
Time frame: at the end of the 8 week treatment period
Started Dec 2023 (actual). Primary completion is estimated for Nov 2025, 23 months after the start.
Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 23 months is close to that.
Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →